Archon Biosciences emerged from stealth to commercialize engineered protein "antibody cages" (AbCs) that scaffold and multiply the effective binding of antibodies to targets. The company uses a proprietary protein design platform built on generative design and simulation tools licensed from Baker Lab at the University of Washington. Archon couples that platform with rapid in-house manufacturing and testing to accelerate biologics development and believes AbCs can turn marginal antibody interactions into robust therapeutic effects. The work underpinning AbCs is documented in a paper published in Science and the startup was spun out as the first company from Baker Lab. Archon is led by co-founder and CEO James Lazarovits and is based in Seattle. Financially, the company announced a $20 million seed financing and has additionally received about $7 million in grants from various institutes and government agencies.

Total raised

$27M

Funding rounds

2

Latest round

Grant

Latest activity

Oct 2024